194668-50-3

Basic information

• Product Name: 5-Bromo-2-(piperidin-4-yloxy)pyridine
• Synonyms: 5-Bromo-2-(piperidin-4-yloxy)pyridine;2-(PIPERIDIN-4-YLOXY)-5-BROMOPYRIDINE
• CAS NO: 194668-50-3
• Molecular Formula: C10H13BrN2O
• Molecular Weight: 257.13
• Mol File: 194668-50-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 323.2°C at 760 mmHg
• Flash Point: 149.2°C
• Appearance: /
• Density: 1.417g/cm³
• Vapor Pressure: 0.000267mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-2-(piperidin-4-yloxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-(piperidin-4-yloxy)pyridine(194668-50-3)
• EPA Substance Registry System: 5-Bromo-2-(piperidin-4-yloxy)pyridine(194668-50-3)

Safety Data

• Hazardous Substances Data: 194668-50-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H13BrN2O/c11-8-1-2-10(13-7-8)14-9-3-5-12-6-4-9/h1-2,7,9,12H,3-6H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 766-11-0 5-bromo-2-fluoropyridine 
• 624-28-2 2,5-dibromopyridine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 1015242-41-7 5-bromo-2-((1-methylpiperidin-4-yl)oxy)pyridine 

Relevant articles and documents

Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl- oxazolidinones leading to a promising antibacterial agent

The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low hERG inhibition. With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents. Oxazolidinone ring substitution on the pyridyl ring generated analogues with antibacterial activity superior to imidazolidinone ring. Solubility was enhanced by the incorporation of polar groups, especially when compounds were converted to their prodrugs. Among the prodrugs, compound 85 exhibited excellent solubility and a good pharmacokinetic profile. In a MRSA systemic infection model, compound 85 displayed an ED 50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.

AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS

Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

Heterocyclic compounds useful as pharmaceutical agents

Compounds of formula (I) in which all variables are defined in the description and their salts inhibit the enzyme oxido squalene cyclase and are useful in treating hypercholesterolemia and also as anti-fungal agents. Processes for their preparation are also described together with their use in medicine.